undamentalytics Newsletter

Scheller Richard H: insider trades

Officer, Director at 4 companies we cover. 1 open-market purchase and 6 sales not made under a pre-set plan, reported from August 14, 2017 to September 16, 2025.

Would copying Scheller Richard H’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. After their sales, the shares moved −69.3% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it. None of their purchases could be priced, so there is no copy portfolio.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Scheller Richard H: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 6 −2.4% −9.9% 83% 4 0.17 0.88 No reliable evidence
Sales, 12 months after the report 6 −69.3% −72.5% 100% 4 −4.49 0.021 Some evidence: seller right
Sales, 12 months after the trade 6 −58.3% −64.3% 100% 4 −3.80 0.032 Some evidence: seller right

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Bridgebio Pharma, Inc. BBIO See Remarks04December 17, 2020August 6, 2021
Xenon Pharmaceuticals Inc. XENE —10August 14, 2017August 14, 2017
Alector, Inc. ALEC —01August 23, 2024August 23, 2024
Maze Therapeutics, Inc. MAZE —01September 16, 2025September 16, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
September 16, 2025September 15, 2025 MAZE Sale $464,043 +68.4%−21.3%−12.5%
August 23, 2024August 22, 2024 ALEC Sale $228,330 −32.9%−72.5%−70.9%
August 6, 2021August 4, 2021 BBIO Sale $733,350 −6.3%−73.6%−76.8%
December 23, 2020December 21, 2020 BBIO Sale $3,945,056 −25.5%−114.7%−63.1%
December 21, 2020December 18, 2020 BBIO Sale $1,951,987 −13.5%−72.5%−61.0%
December 17, 2020December 15, 2020 BBIO Sale $1,898,410 −4.5%−61.0%−65.5%
August 14, 2017August 10, 2017 XENE Purchase $19,950 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Scheller Richard H traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.